 |
|
|
| |
Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies
|
| |
| |
AASLD 2020 virtual Nov 11-16
Reported by Jules Levin
Giuliano Rizzardini1, Michael Gschwantler2, Stefan Bourgeois3, Beat Mullhaupt4, Wodzimierz Mazur5, Mark Bondin6, Zhenzhen Zhang6, Fiona Marra7, Ella Veitsman8, Konstantinos Mimidis9, Nuno Marques10 and Juliette Foucher11, (1)1st Division of Infectious Diseases, Asst Fatebenefratelli-Sacco, (2)Department of Internal Medicine IV, Wilhelminenspital, (3)Stuivenberg Zna, (4)Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, (5)Clinical Department of Infectious Diseases, Medical University of Silesia, (6)Abbvie Inc., (7)University of Liverpool Hepatology Drug Interactions Group, (8)Liver Unit, Rambam Health Care Campus, (9)First Department of Internal Medicine, Democritus University of Thrace Medical School, (10)Infectious Diseases Service, Hospital Garcia De Orta Epe, (11)Hopital Du Haut-Leveque
|
| |
|
|
|
|
|
